Igor Snast

Igor Snast

Auto-generated profile, based on publicly available information

Igor Snast

Laser Unit, Division of Dermatology, Rabin Medical Center, Petah Tikva, Israel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ISI. Snast
I. Snast
OROfer Reiter
Ofer Reiter
LAL. Atzmony
L. Atzmony
YLY.A. Leshem
Y.A. Leshem
EHE. Hodak
E. Hodak
LPLev Pavlovsky
Lev Pavlovsky

1 September 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ISIgor Snast
Igor Snast
ADAdam Dalal
Adam Dalal
GTGilad Twig
Gilad Twig
NANadav Astman
Nadav Astman
RKRon Kedem
Ron Kedem
ALAssi Levi
Assi Levi

14 April 2020 in Dermatology
Verified
Journal Article
Closed access
PDF file
ISIgor Snast
Igor Snast
ESEran Sharon
Eran Sharon
RKRan Kaftory
Ran Kaftory
YNYehonatan Noyman
Yehonatan Noyman
MOMeital Oren-Shabtai
Meital Oren-Shabtai
ALAssi Levi
Assi Levi
Introduction: Surgery is commonly regarded as the mainstay of treatment of extramammary Paget disease (EMPD); however, nonsurgical approaches have gained popularity in recent years. Objectives: To review the published evidence for the efficacy and safety of nonsurgical modes of therapy for EMPD. Methods: A systematic review and meta-analysis of nonsurgical EMPD treatments was performed. The primary outcome was complete response (CR); secondary outcomes were clinical regression by ≥50%, adverse events, and recurrence rate. Results: The systematic review included 43 observational studies (341 patients; 7 prospective cohort studies, 19 retrospective cohort studies, and 17 cases series) evaluating 5 treatment modalities. Imiquimod (13 studies, 110 patients) administered at variable doses ranging from daily to twice weekly for 2–56 weeks demonstrated CR of 54% (95% CI, 40–67%; I2 = 37%) and had a satisfactory safety profile. In 14 heterogeneous studies (122 patients) evaluating photodynamic therapy (PDT), only 36% (95% CI, 22–53%; I2 = 52%) of patients achieved CR. Radiotherapy (12 studies, 67 patients) showed CR of 97%, but was associated with local and systemic side effects. Ablative lasers and topical fluorouracil and calcipotriene lacked adequate evidence of efficacy. Conclusions: Imiquimod and radiotherapy are the most appropriate nonsurgical modalities for EMPD treatment given their good efficacy and safety profile. PDT has limited efficacy but may be appropriate in selected clinical settings.

3 July 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
ISIgor Snast
Igor Snast
SSShany Sherman
Shany Sherman
RHRoie Holzman
Roie Holzman
EHEmmilia Hodak
Emmilia Hodak
LPLev Pavlovsky
Lev Pavlovsky

15 September 2020 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
ESEran Sharon
Eran Sharon
ISIgor Snast
Igor Snast
MLMoshe Lapidoth
Moshe Lapidoth
RKRan Kaftory
Ran Kaftory
DMDaniel Mimouni
Daniel Mimouni
ALAssi Levi
Assi Levi

31 July 2018 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
ALAssi Levi
Assi Levi
EHEmmilia Hodak
Emmilia Hodak
CEClaes David Enk
Claes David Enk
ISIgor Snast
Igor Snast
DSDan Slodownik
Dan Slodownik
MLMoshe Lapidoth
Moshe Lapidoth
Summary: Background: Actinic cheilitis (AC) is a common, chronic premalignant condition resulting from protracted sun exposure affecting the vermilion border of the lower lip. Treatment of AC aims at terminating the progression to squamous cell carcinoma by obliterating the primary lesion, and includes ablative methods; nonablative modalities such as cryotherapy, electrodessication, chemical peeling, topical imiquimod and 5‐fluorouracil; and photodynamic therapy (PDT). Daylight‐activated PDT, in which natural daylight serves as the light source, showed promising results in the treatment of actinic keratoses with substantially less pain than conventional PDT.Purpose: To determine the safety and efficacy of daylight PDT in a series of patients with AC.Methods: Eleven patients with AC were treated with daylight PDT. All patients underwent repeated treatment sessions until clinical and histological remission were achieved.Results: Cure rate was 91% (10 of 11 patients, three females/eight males; mean age 59.2 ± 14.4 years). Mean number of treatments to attain cure was 2.7. Patients experienced mild erythema and minimal to no pain during treatment.Conclusions: Daylight PDT is a promising modality for the treatment of AC, with impressive cosmetic results and few side effects.